Molbio Diagnostics Eyes ₹940 Crore Through IPO to Boost Expansion

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, is set to launch an initial public offering (IPO) to raise a total of ₹940 crore. The company plans to use ₹200 crore from the fresh issue of shares for capital expenditures and to elevate its operational capabilities. Additionally, an offer for sale is expected to generate ₹740 crore, reducing the promoter group's stake from 46.6% to 43%.

Global Presence and Product Strength

Established in 2000, Molbio Diagnostics operates six manufacturing facilities across India and serves clients in over 90 countries. The company has carved a niche in providing diagnostic solutions for infectious and non-communicable diseases. Its flagship product, the Truenat platform, offers a portable diagnostic solution capable of delivering accurate results in under an hour, making it ideal for resource-limited settings.

Molbio's product portfolio includes molecular testing solutions for over 30 diseases, supported by 43 diagnostic assays. A significant portion of its revenue, approximately 74%, is derived from the sale of test kits, with tuberculosis diagnostic kits contributing 70% of this figure. The company's clientele includes government health programs, diagnostic labs, hospitals, and international healthcare organizations.

Financial Performance and Market Position

Between FY24 and FY26, Molbio Diagnostics reported a 31.5% annual rise in revenue from operations, reaching ₹1,445.7 crore. Net profit during this period surged by 40.2% to ₹164.1 crore. The company's EBITDA increased by 33.2% to ₹328.2 crore, with an EBITDA margin improvement from 22% in FY24 to 22.6% in FY26. On a year-on-year basis, FY26 saw a 41.7% revenue jump, a 27.9% rise in EBITDA, and an 18.4% increase in net profit.

Molbio's valuation post-IPO suggests a price-earnings (P/E) multiple of up to 57, positioning it alongside other healthcare diagnostics and medical device companies like Poly Medicure, Dr. Lal PathLabs, and Metropolis Healthcare, which trade at P/E multiples between 54 and 81.

Investor Considerations

The IPO presents a potential opportunity for high-risk investors seeking long-term growth. With substantial backing from government and international aid agencies, accounting for over 80% of its revenue, Molbio's market presence is robust. However, its revenue is heavily concentrated among a few top clients, indicating potential risks.

As Molbio aims to further its reach and enhance its technological offerings, the capital raised through the IPO could play a crucial role in its strategic expansion plans. Investors will be closely watching Molbio's ability to maintain its growth trajectory and expand its client base in the competitive diagnostics market.